Fc Variant Amino Acid Substitutions for Complement Activity

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current therapeutic antibodies, such as anti-CD20 antibodies, face limitations in efficacy due to inhibitory effects from complement protein C3 on natural killer cell activation and the absence of complement-mediated cytotoxicity in vitro, casting doubt on the effectiveness of enhancing complement activity for therapeutic purposes.

Innovation Solution

Development of novel Fc variants with specific amino acid substitutions that enhance binding to complement protein C1q and FcγR, thereby improving complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC), and antibody-dependent cellular phagocytosis (ADCP) effector functions.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If complement activity is enhanced to improve therapeutic antibody efficacy, then complement-dependent cytotoxicity (CDC) increases, but complement protein C3 inhibits natural killer cell activation and ADCC

Engineering Contradiction:

Improvetherapeutic antibody efficacyVSAvoidcomplement protein C3 inhibition

Core Design Contradiction:

ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The patent applies local quality by making specific amino acid substitutions at particular positions (267, 268, 324) in the Fc region to selectively enhance C1q binding affinity and CDC activity while preserving or maintaining ADCC function. This localized modification approach allows differential optimization of complement recruitment without uniformly affecting all effector functions.

Inventive Principle:

Principle #3Local quality

Solution Approach 2:

The patent employs parameter changes by modifying amino acid residues at specific positions in the Fc region to alter the physical-chemical properties of C1q binding. The substitutions (267E, 268F, 324T) change the binding parameters and affinity for C1q, thereby enhancing CDC activity while navigating the complex balance with other effector functions.

Inventive Principle:

Principle #35Parameter changes

2Reliability

If Fc variants are designed to enhance binding to C1q and improve CDC, then complement-mediated cytotoxicity increases, but the complexity of antibody engineering increases

Engineering Contradiction:

Improvecomplement-mediated cytotoxicityVSAvoidantibody engineering complexity

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent applies segmentation by dividing the Fc region into specific editable positions (267, 268, 324) that can be independently modified. This modular approach to engineering allows systematic optimization of C1q binding through discrete amino acid substitutions rather than requiring comprehensive redesign of the entire Fc region.

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The patent uses parameter changes by systematically varying amino acid residues at specific positions to optimize C1q binding affinity. The defined substitutions (267E, 268F, 324T) represent controlled parameter modifications that enhance CDC activity through predictable changes in binding characteristics.

Inventive Principle:

Principle #35Parameter changes

3Reliability

If multiple amino acid substitutions are introduced to enhance both C1q binding and FcγR binding, then both CDC and ADCC are improved, but the manufacturing precision requirements increase

Engineering Contradiction:

Improveeffector function activityVSAvoidamino acid substitution precision

Core Design Contradiction:

ReliabilityVSManufacturing precision

Solution Approach 1:

The patent applies segmentation by identifying and modifying specific amino acid positions (267, 268, 324) independently within the Fc region. This segmented approach allows precise control over which residues are substituted, enabling systematic optimization of both C1q and FcγR binding through defined combinations of mutations.

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The patent employs parameter changes by introducing specific amino acid substitutions at predetermined positions to simultaneously enhance C1q binding for CDC and FcγR binding for ADCC. The defined substitutions represent controlled parameter modifications that achieve dual-function optimization with predictable outcomes.

Inventive Principle:

Principle #35Parameter changes

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The Fc variants demonstrate increased efficacy by enhancing CDC, ADCC, and ADCP activities, leading to improved therapeutic outcomes for antibodies targeting CD20+ cells, as shown by increased cytotoxicity and phagocytosis in experimental settings.

Implementation Method 1

substitutions that improve binding to complement protein C1q

Methodology Applied

Scientific EffectProtein-protein binding:

Implementation Method 2

substitutions that improve binding to complement protein C1q or enhance CDC

Methodology Applied

Scientific EffectProtein-protein binding:

Data Source

PatentUS9475881B2Antibody variants with enhanced complement activity

Publication Date: 2016.10.25 XENCOR INC

AI summary

The present invention relates to novel Fc variants that comprise at least one novel amino acid residue which may provide for enhanced effector function. More specifically, this invention provides Fc variants that have modified binding affinity to one or more Fc receptor or ligand (e.g., Fc gamma R, C1q). Additionally, the Fc variants have altered complement dependent cytotoxicity (CDC) activity and/or antibody-dependent cell-mediated cytotoxicity (ADCC). The invention further provides methods and protocols for the application of said Fc variants, particularly for therapeutic purposes.